Trial reportCancer chemotherapy and pharmacology2022
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Trial report in Cancer chemotherapy and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02454972 (A Multicenter Phase II Clinical Trial of Lurbinectedin), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer.Future oncology (London, England) · 2025Article
- CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.Clinical and translational science · 2025Article
- A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.Scientific reports · 2024Article
- Article
- A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.Frontiers in oncology · 2023Article
- Lurbinectedin-induced thrombocytopenia: the role of body surface area.Cancer chemotherapy and pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThese exposure-response (E-R) analyses integrated lurbinectedin effects on key efficacy and safety variables in relapsed SCLC to determine the adequacy of the dose regimen of 3.2 mg/m
methodsLogistic models and Cox regression analyses were applied to correlate lurbinectedin exposure metrics (AUC
resultsEffect of lurbinectedin AUC
conclusionsThe relationships evidenced in this integrated E-R analysis support a favorable benefit-risk profile for lurbinectedin 3.2 mg/m
trial registrationClinicaltrials.gov: NCT02454972; registered May 27, 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.